Skip to main content

Table 3 Risk factors for death. Univariate and multivariate Cox models

From: Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

  Univariate model   Multivariate model  
Hazard Ratio (95% confidence interval) p-value Hazard Ratio (95% confidence interval) p-value
Region   < 0.01   < 0.01
 Eastern Europe 1   1  
 Western/Southern Europe 0.16(0.08–0.31)   0.19 (0.09–0.39)  
 Latin America 0.42(0.25–0.70)   0.44 (0.25–0.77)  
Age, years   0.69   0.87
 30 vs 20 1.07(0.64–1.80)   1.12 (0.64–1.97)  
 40 vs 20 1.07(0.47–2.42)   1.29 (0.53–3.13)  
 50 vs 20 0.93(0.43–2.00)   1.53 (0.66–3.55)  
Male 1.26(0.81–1.95) 0.30 1.00 (0.62–1.60) 0.99
Disseminated TB 1.57(1.06–2.33) 0.03 1.38 (0.92–2.06) 0.12
IDU 1.89(1.31–2.74) < 0.01 1.19 (0.78–1.83) 0.42
TB susceptibility   < 0.01   0.52
 No MDR vs MDR 0.41(0.24–0.71)   0.72 (0.41–1.27)  
 No Resistance test vs MDR 0.52(0.31–0.88)   0.84(0.49–1.46)  
Efavirenz 1.47(0.96–2.24) 0.07 1.13(0.72–1.78) 0.59
ART naïve 1.06(0.73–1.54) 0.74 0.64(0.43–0.96) 0.03
CD4+ at TB diagnosis (cells/mm3)   < 0.01   < 0.01
 100 vs 50 0.63(0.53–0.76)   0.61(0.50–0.73)  
 200 vs 50 0.35(0.25–0.51)   0.33(0.23–0.48)  
 350 vs 50 0.27(0.17–0.42)   0.27(0.17–0.42)  
  1. Note: Cox regression model in which patients were stratified by rifamicin use at TB diagnosis
  2. Nine hundred sixty-five patients were included in this model. IDU Injection Drug User, MDR-TB Multi-drug resistant tuberculosis